Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This appears to be a **multi-ingredient compounded pharmaceutical mixture** containing isopropyl alcohol, triamcinolone acetonide, dexamethasone sodium phosphate, and bupivacaine. Pharmacologically, the mixture combines two corticosteroids that act as **glucocorticoid receptor agonists** to suppress inflammatory gene transcription and reduce edema and immune-cell activity, together with **bupivacaine**, a local anesthetic that blocks voltage-gated sodium channels to provide analgesia. Isopropyl alcohol in this context most plausibly functions as a procedural antiseptic or solvent rather than as a therapeutic active ingredient. Based on the provided context, this specific four-component combination is not identifiable as a distinct standardized marketed drug product with a unique INN or well-established brand; the surrounding indication text instead matches general corticosteroid labeling and therefore does not specifically validate a unique development program for this exact combination.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on isopropyl alcohol + triamcinolone acetonide + dexamethasone sodium phosphate + bupivacaine.